RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice
Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is...
Saved in:
Published in | Current controlled trials in cardiovascular medicine Vol. 24; no. 1; p. 615 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
28.09.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. Keywords: Antidepressants, Discontinuation, Deprescribing, Primary care, Withdrawal, Tapering, Long-term antidepressant use, Randomised controlled trial |
---|---|
AbstractList | Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. Keywords: Antidepressants, Discontinuation, Deprescribing, Primary care, Withdrawal, Tapering, Long-term antidepressant use, Randomised controlled trial Abstract Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. BackgroundMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies.MethodsDesign3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity).DiscussionThe RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients.Trial registrationANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. BACKGROUNDMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies.METHODSDESIGN: 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1.SETTINGprimary care general practices in southeast Queensland, Australia.POPULATIONadults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+.INTERVENTIONRELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs.OUTCOME MEASURESthe primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks.SECONDARY OUTCOMESat 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs.SAMPLE SIZE653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity).DISCUSSIONThe RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients.TRIAL REGISTRATIONANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. |
ArticleNumber | 615 |
Audience | Academic |
Author | Freeman, Chris Scott, Ian Cleetus, MaryAnne Zwar, Nicholas Thrift, Karen Panahi, Idin Morgan, Mark Wallis, Katharine A Donald, Maria Horowitz, Mark Moncrieff, Joanna Ware, Robert S Byrnes, Joshua |
Author_xml | – sequence: 1 fullname: Wallis, Katharine A – sequence: 2 fullname: Donald, Maria – sequence: 3 fullname: Horowitz, Mark – sequence: 4 fullname: Moncrieff, Joanna – sequence: 5 fullname: Ware, Robert S – sequence: 6 fullname: Byrnes, Joshua – sequence: 7 fullname: Thrift, Karen – sequence: 8 fullname: Cleetus, MaryAnne – sequence: 9 fullname: Panahi, Idin – sequence: 10 fullname: Zwar, Nicholas – sequence: 11 fullname: Morgan, Mark – sequence: 12 fullname: Freeman, Chris – sequence: 13 fullname: Scott, Ian |
BookMark | eNptks9u1DAQxiNUJNrCC3CyxKUcUvw3cbigVRWg0kpILZwtrz1JXSV2cLKt9r36gMx2K6AIWZZH9vf97BnPSXEUU4SieMvoOWO6-jAzQStRUo6zrmRV3r8ojlktVVlxpo7-il8VJ_N8S6kUjZDHxcNVu25X1y05u2p9hnkOsSfrFPtyafNIVnEJHqb9gY0L2V637z-SKacluTSQLmViiSgtKqds-9EuwRE3bOcFMsk2-jSGGTxxKS45DQOGSw52INB14JZwBxHJZRinAUaIC_pTJDe7TQ6o3E1QMhIi6VGW0YV3oMnB6-JlZ4cZ3jytp8WPz-33i6_l-tuXy4vVunRKsqVk0lXSOy-FV43WugKltefc1VAr5nlDneKKWQm1s6yrNnwjK4uFhA11wm_EaXF54Ppkb82Uw2jzziQbzONGyr2xGR80gFFO0gashkY6hNS2EUpJL3inbSeZQ9anA2vabkbwDrPFlJ5Bn5_EcGP6dGcYVaLmvELC2RMhp59bmBeDxXUwDDZC2s6G65o2DVfNXvruH-lt2uaItUJV1WhKtRZ_VL3FDELsEl7s9lCzqqua0rrRClXn_1Hh8DAG_FjoAu4_M_CDweU0zxm630kyavbdag7darBbzWO3mnvxC3I-4Ts |
CitedBy_id | crossref_primary_10_1071_PY23168 crossref_primary_10_1071_PY23046 crossref_primary_10_1016_j_jad_2024_04_060 crossref_primary_10_1016_j_jadr_2024_100765 |
Cites_doi | 10.1177/2045125320921694 10.1177/2045125320980573 10.1176/appi.ajp.161.5.826 10.3399/bjgpopen17X101265 10.1016/j.sxmr.2017.07.002 10.2147/PPA.S110632 10.1177/2045125321991274 10.1192/bjp.bp.108.061960 10.1016/j.jpsychires.2023.03.013 10.1097/00005650-199603000-00003 10.1177/0897190012467210 10.1186/1477-7525-10-156 10.3399/BJGP.2020.0913 10.1177/0004867420979353 10.1046/j.1525-1497.2001.016009606.x 10.1177/0004867417721018 10.1016/j.addbeh.2018.08.027 10.1097/NMD.0b013e318156816f 10.1787/ae3016b9-en 10.1177/20451253211039327 10.1177/2045125320967183 10.1370/afm.2094 10.1093/heapro/dal017 10.1177/0269881113517957 10.1097/MLR.0b013e3182408812 10.1177/0004867415621392 10.1007/s40263-022-00960-y 10.1177/2045125320981174 10.1001/archinte.166.10.1092 10.5694/mja2.50522 10.1136/bmj.d4551 10.1016/S0749-3797(01)00350-6 10.1016/S2215-0366(19)30032-X 10.31128/AJGP-02-21-5828 10.1159/000506868 10.1016/j.jad.2018.10.107 10.1192/bjp.bp.108.051110 10.1071/HC17018 10.1080/08870449908407311 10.1192/bja.2021.62 10.7326/0003-4819-146-5-200703060-00004 10.1136/bmjopen-2020-039053 10.1177/20451253231171518 10.1186/1748-5908-4-50 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 BioMed Central Ltd. The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. BioMed Central Ltd., part of Springer Nature 2023 |
Copyright_xml | – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: BioMed Central Ltd., part of Springer Nature 2023 |
DBID | AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13063-023-07646-w |
DatabaseName | CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1745-6215 |
EndPage | 615 |
ExternalDocumentID | oai_doaj_org_article_5c409ea8e94c46a7a93554d32f8af41c A767007985 10_1186_s13063_023_07646_w |
GeographicLocations | Australia Queensland Australia United Kingdom--UK |
GeographicLocations_xml | – name: Australia – name: United Kingdom--UK – name: Queensland Australia |
GrantInformation_xml | – fundername: ; grantid: MRFAR000079 – fundername: ; grantid: PRC3 - 2015744 |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C24 C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S PGMZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO FRP K9. PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
ID | FETCH-LOGICAL-c541t-14c64dcd43d598886e588d22c7e751d290c5251a4e7ca1f6b2b46a306eb0c3db3 |
IEDL.DBID | RPM |
ISSN | 1745-6215 |
IngestDate | Tue Oct 22 15:10:31 EDT 2024 Tue Sep 17 21:29:20 EDT 2024 Fri Oct 25 09:47:37 EDT 2024 Mon Dec 16 22:53:29 EST 2024 Tue Nov 19 21:44:06 EST 2024 Tue Nov 12 23:47:53 EST 2024 Fri Nov 22 07:15:02 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c541t-14c64dcd43d598886e588d22c7e751d290c5251a4e7ca1f6b2b46a306eb0c3db3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-2580-9362 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537226/ |
PQID | 2869800883 |
PQPubID | 44365 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5c409ea8e94c46a7a93554d32f8af41c pubmedcentral_primary_oai_pubmedcentral_nih_gov_10537226 proquest_miscellaneous_2870992596 proquest_journals_2869800883 gale_infotracmisc_A767007985 gale_infotracacademiconefile_A767007985 crossref_primary_10_1186_s13063_023_07646_w |
PublicationCentury | 2000 |
PublicationDate | 2023-09-28 |
PublicationDateYYYYMMDD | 2023-09-28 |
PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-28 day: 28 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Current controlled trials in cardiovascular medicine |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – sequence: 0 name: BioMed Central – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | GS Malhi (7646_CR8) 2021; 55 A Bala (7646_CR10) 2018; 6 PC Groot (7646_CR27) 2021; 11 C Coupland (7646_CR13) 2011; 343 MA Horowitz (7646_CR25) 2019; 6 H Maheswaran (7646_CR45) 2012; 10 A Guy (7646_CR22) 2020; 10 7646_CR32 K Kroenke (7646_CR50) 2001; 16 7646_CR31 7646_CR30 R Horne (7646_CR49) 1999; 14 RL Spitzer (7646_CR52) 2006; 166 M Donald (7646_CR39) 2021; 71 K Hodgson (7646_CR43) 2014; 28 K Kroenke (7646_CR53) 2007; 146 E White (7646_CR19) 2021; 11 G Cruickshank (7646_CR21) 2008; 5 J Price (7646_CR11) 2009; 195 F Cosci (7646_CR17) 2020; 89 GM Curran (7646_CR36) 2012; 50 SM Orsillo (7646_CR48) 2007; 195 7646_CR20 SR Kjosavik (7646_CR2) 2016; 50 NR Ogle (7646_CR33) 2013; 26 J Davies (7646_CR16) 2019; 97 7646_CR18 JH Meyer (7646_CR29) 2004; 161 7646_CR14 LJ Damschroder (7646_CR54) 2009; 4 A Framer (7646_CR26) 2021; 11 MJ Huijbers (7646_CR55) 2020; 10 RE Glasgow (7646_CR40) 2001; 21 7646_CR4 R Eveleigh (7646_CR35) 2018; 1 7646_CR1 7646_CR7 C Cartwright (7646_CR12) 2016; 10 R Uher (7646_CR44) 2009; 195 7646_CR6 RE Glasgow (7646_CR41) 2006; 21 J van Os (7646_CR28) 2023; 13 J Brett (7646_CR3) 2017; 51 MP Hengartner (7646_CR15) 2020; 10 7646_CR47 S Gilbody (7646_CR51) 2007; 57 KA Wallis (7646_CR38) 2017; 9 JE Ware (7646_CR42) 1996; 34 MP Hengartner (7646_CR5) 2020; 10 J Read (7646_CR23) 2023; 161 7646_CR46 KA Wallis (7646_CR34) 2021; 50 KA Wallis (7646_CR37) 2017; 15 E Maund (7646_CR24) 2019; 245 J Rothmore (7646_CR9) 2020; 212 |
References_xml | – volume: 10 start-page: 204512532092169 year: 2020 ident: 7646_CR5 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125320921694 contributor: fullname: MP Hengartner – volume: 10 start-page: 204512532098057 year: 2020 ident: 7646_CR15 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125320980573 contributor: fullname: MP Hengartner – volume: 161 start-page: 826 issue: 5 year: 2004 ident: 7646_CR29 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.161.5.826 contributor: fullname: JH Meyer – volume: 1 start-page: 17X101265 issue: 4 year: 2018 ident: 7646_CR35 publication-title: BJGP Open doi: 10.3399/bjgpopen17X101265 contributor: fullname: R Eveleigh – volume: 6 start-page: 29 issue: 1 year: 2018 ident: 7646_CR10 publication-title: Sex Med Rev doi: 10.1016/j.sxmr.2017.07.002 contributor: fullname: A Bala – volume: 10 start-page: 1401 year: 2016 ident: 7646_CR12 publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S110632 contributor: fullname: C Cartwright – volume: 11 start-page: 204512532199127 year: 2021 ident: 7646_CR26 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125321991274 contributor: fullname: A Framer – volume: 195 start-page: 202 issue: 3 year: 2009 ident: 7646_CR44 publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.108.061960 contributor: fullname: R Uher – volume: 161 start-page: 298 year: 2023 ident: 7646_CR23 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2023.03.013 contributor: fullname: J Read – ident: 7646_CR20 – ident: 7646_CR47 – volume: 5 start-page: 105 issue: 2 year: 2008 ident: 7646_CR21 publication-title: Ment Health Fam Med contributor: fullname: G Cruickshank – ident: 7646_CR30 – volume: 34 start-page: 220 issue: 3 year: 1996 ident: 7646_CR42 publication-title: Med Care doi: 10.1097/00005650-199603000-00003 contributor: fullname: JE Ware – volume: 26 start-page: 389 issue: 4 year: 2013 ident: 7646_CR33 publication-title: J Pharm Pract doi: 10.1177/0897190012467210 contributor: fullname: NR Ogle – volume: 10 start-page: 156 issue: 1 year: 2012 ident: 7646_CR45 publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-10-156 contributor: fullname: H Maheswaran – volume: 71 start-page: E508 issue: 708 year: 2021 ident: 7646_CR39 publication-title: Br J Gen Pract doi: 10.3399/BJGP.2020.0913 contributor: fullname: M Donald – volume: 55 start-page: 7 issue: 1 year: 2021 ident: 7646_CR8 publication-title: Aust N Z J Psychiatry doi: 10.1177/0004867420979353 contributor: fullname: GS Malhi – volume: 16 start-page: 606 issue: 9 year: 2001 ident: 7646_CR50 publication-title: J Gen Intern Med doi: 10.1046/j.1525-1497.2001.016009606.x contributor: fullname: K Kroenke – ident: 7646_CR6 – volume: 51 start-page: 990 issue: 10 year: 2017 ident: 7646_CR3 publication-title: Aust N Z J Psychiatry doi: 10.1177/0004867417721018 contributor: fullname: J Brett – volume: 97 start-page: 111 year: 2019 ident: 7646_CR16 publication-title: Addict Behav doi: 10.1016/j.addbeh.2018.08.027 contributor: fullname: J Davies – ident: 7646_CR31 – volume: 195 start-page: 830 issue: 10 year: 2007 ident: 7646_CR48 publication-title: J Nerv Ment Dis doi: 10.1097/NMD.0b013e318156816f contributor: fullname: SM Orsillo – ident: 7646_CR1 doi: 10.1787/ae3016b9-en – volume: 11 start-page: 204512532110393 year: 2021 ident: 7646_CR27 publication-title: Ther Adv Psychopharmacol doi: 10.1177/20451253211039327 contributor: fullname: PC Groot – volume: 10 start-page: 204512532096718 year: 2020 ident: 7646_CR22 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125320967183 contributor: fullname: A Guy – volume: 15 start-page: 341 issue: 4 year: 2017 ident: 7646_CR37 publication-title: Ann Fam Med doi: 10.1370/afm.2094 contributor: fullname: KA Wallis – ident: 7646_CR7 – volume: 21 start-page: 245 issue: 3 year: 2006 ident: 7646_CR41 publication-title: Health Promot Int doi: 10.1093/heapro/dal017 contributor: fullname: RE Glasgow – volume: 28 start-page: 142 issue: 2 year: 2014 ident: 7646_CR43 publication-title: J Psychopharmacol doi: 10.1177/0269881113517957 contributor: fullname: K Hodgson – volume: 50 start-page: 217 issue: 3 year: 2012 ident: 7646_CR36 publication-title: Med Care doi: 10.1097/MLR.0b013e3182408812 contributor: fullname: GM Curran – volume: 50 start-page: 1180 issue: 12 year: 2016 ident: 7646_CR2 publication-title: Aust N Z J Psychiatry doi: 10.1177/0004867415621392 contributor: fullname: SR Kjosavik – ident: 7646_CR14 doi: 10.1007/s40263-022-00960-y – volume: 11 start-page: 204512532098117 year: 2021 ident: 7646_CR19 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125320981174 contributor: fullname: E White – volume: 57 start-page: 650 issue: 541 year: 2007 ident: 7646_CR51 publication-title: Br J Gen Pract contributor: fullname: S Gilbody – volume: 166 start-page: 1092 issue: 10 year: 2006 ident: 7646_CR52 publication-title: Arch Intern Med doi: 10.1001/archinte.166.10.1092 contributor: fullname: RL Spitzer – volume: 212 start-page: 329 issue: 7 year: 2020 ident: 7646_CR9 publication-title: Med J Aust doi: 10.5694/mja2.50522 contributor: fullname: J Rothmore – volume: 343 start-page: d4551 year: 2011 ident: 7646_CR13 publication-title: BMJ doi: 10.1136/bmj.d4551 contributor: fullname: C Coupland – volume: 21 start-page: 189 issue: 3 year: 2001 ident: 7646_CR40 publication-title: Am J Prev Med doi: 10.1016/S0749-3797(01)00350-6 contributor: fullname: RE Glasgow – ident: 7646_CR32 – volume: 6 start-page: 538 issue: 6 year: 2019 ident: 7646_CR25 publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(19)30032-X contributor: fullname: MA Horowitz – volume: 50 start-page: 954 issue: 12 year: 2021 ident: 7646_CR34 publication-title: Aust J Gen Pract doi: 10.31128/AJGP-02-21-5828 contributor: fullname: KA Wallis – volume: 89 start-page: 283 issue: 5 year: 2020 ident: 7646_CR17 publication-title: Psychother Psychosom doi: 10.1159/000506868 contributor: fullname: F Cosci – volume: 245 start-page: 38 year: 2019 ident: 7646_CR24 publication-title: J Affect Disord doi: 10.1016/j.jad.2018.10.107 contributor: fullname: E Maund – volume: 195 start-page: 211 issue: 3 year: 2009 ident: 7646_CR11 publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.108.051110 contributor: fullname: J Price – volume: 9 start-page: 145 issue: 2 year: 2017 ident: 7646_CR38 publication-title: J Prim Health Care doi: 10.1071/HC17018 contributor: fullname: KA Wallis – volume: 14 start-page: 1 issue: 1 year: 1999 ident: 7646_CR49 publication-title: Psychol Health doi: 10.1080/08870449908407311 contributor: fullname: R Horne – ident: 7646_CR18 doi: 10.1192/bja.2021.62 – ident: 7646_CR4 – ident: 7646_CR46 – volume: 146 start-page: 317 issue: 5 year: 2007 ident: 7646_CR53 publication-title: Ann Intern Med doi: 10.7326/0003-4819-146-5-200703060-00004 contributor: fullname: K Kroenke – volume: 10 start-page: e039053 issue: 11 year: 2020 ident: 7646_CR55 publication-title: BMJ Open doi: 10.1136/bmjopen-2020-039053 contributor: fullname: MJ Huijbers – volume: 13 start-page: 204512532311715 year: 2023 ident: 7646_CR28 publication-title: Ther Adv Psychopharmacol doi: 10.1177/20451253231171518 contributor: fullname: J van Os – volume: 4 start-page: 50 issue: 1 year: 2009 ident: 7646_CR54 publication-title: Implement Sci doi: 10.1186/1748-5908-4-50 contributor: fullname: LJ Damschroder |
SSID | ssj0043934 ssj0017864 |
Score | 2.413151 |
Snippet | Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or... Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need... BackgroundMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or... BACKGROUNDMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or... Abstract Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 615 |
SubjectTerms | Analysis Antidepressants Automation Clinical practice guidelines Consent Deprescribing Discontinuation Dosage and administration Drug dosages Drug withdrawal Elder care Falls (Accidents) Family medicine Health care reform Intervention Medical care, Cost of Medical practice software Medical research Mental health Patient outcomes Patients Physicians (General practice) Primary care Psychotherapy Psychotropic drugs R&D Research & development Services Sexual disorders Study Protocol Tapering Well being Withdrawal |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9UwFA6yB_FF_InVKREEFQm7-dnEt6t0DNl82BzsLaRJendha8ddL8P_yz_Qk7Qdqz744kOhNCm0-U5OvtOe8wWhd4YHTb2sCasFBCiOaeKAlhOgDiYueOMXPtU7H31XB6fi25k8u7PVV8oJG-SBh4Hbkx4ikOh0NMIL5UqXBMFF4KzRrhHUZ--7YFMwNfhgWGW5mEpktNq7Bk-d_1fCUSqhyM1sGcpq_X_75D_zJO8sPPuP0MORMeLl8KSP0b3YPkH3j8Z_4k_Rr-PqsFqeVPjDcRVyVmu7wodduyJ9tbnEy7Zfj-muMIh4e1J9_IyTOkMHJoCBsmKHOXHQ82rjVlnAFfuLbdJPwLCOhQ4MIQY8prRfwGne6AMPiSCjryTryykPPQGNz3-mQjCcvu8SitctXg3q1ngqynqGTverH18PyLgXA_FS0J5Q4ZUIPggepIGoWUWpdWDMl7GUNDCz8BKokhOx9I42qgbslYNRj_XC81Dz52in7dr4AmEjHW9MQ0vHklwZcLxAZV3yWkdO4VqBPk3Q2KtBcsPmUEUrOwBpAUibgbQ3BfqS0LvtmeSy8wUwIjsakf2XERXofcLepkkNSHs31ibAAyd5LLssUzVTabQs0O6sJ2Dg582T9djRGVxbppUBXq41L9Db2-Z0Z0pwa2O3TX1K4OoQi6oC6ZnVzd5s3tKuz7MgOE2iPMCjX_6PsXiFHrA8UQxhehft9JttfA3Eq6_f5Dn2G8B_LbU priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1di9QwFA26gvgifmLXVSIIKhJ20qRJ6ouM0mWRXR92XZi3kCZpd2C3HeeDxf_lD_Qmk45WwYeBockwbc_NzbnJvScIvS6ZU9QWNclrDgGKyRUxQMsJUIfST1hjJzbUO59-FccX_MusmKUFt1VKqxx8YnTUrrdhjfwwV6IEcqMU-7j4TsKpUWF3NR2hcRvdoTlM5WDPcrYLuKhUgg-FMkocrsBfx11L-EjBBbkZTUZRs_9fz_x3tuQf08_RA3Q_8UY83QL9EN3y3SN09zTtjD9GP8-qk2p6XuG3Z5WLua1di0_6riXranmNp916npJe4VXizXn17gMOGg09GAIG4ooNZsRAz8XStFHGFdurTVBRwDCbuR7MwTucEtuv4Gs87gNv00GSxyTz6yEbPcCNL3-EcjAcVnkJxfMOt1uNazyUZj1BF0fVt8_HJJ3IQGzB6ZpQbgV31nHmihJiZ-ELpVyeW-llQV1eTmwBhMlwL62hjajBAoSBt-7riWWuZk_RXtd3_hnCZWFYUzZUmjyIlgHTc7SoJauVZxSuZej9AI1ebIU3dAxYlNBbIDUAqSOQ-iZDnwJ6u55BNDte6JetTmNQFxaCWW-UL7mF25ImaMtzx_JGmYZTm6E3AXsdhjYgbU2qUIAbDiJZeipDTZMsVZGhg1FPwMCOmwfr0cklrPRvA87Qq11z-GVIc-t8vwl9JDB2iEhFhtTI6kZPNm7p5pdRFpwGaR5g0_v___fn6F4eh0BJcnWA9tbLjX8BxGpdv4yj5xfmxSUi priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dixMxFA3rCuKL-Imjq0QQVCTafE5GEKkyyyJbH3Yt7FvIJJluoTuzdlvW_V_-QG_SmeLoPvlQKJMEpjn3Juc2954g9LLgXlMnK8IqAQGKZZpYoOUEqEMRRrx2IxfrnSff1MFUfD2RJzuov-6om8CLa0O7eJ_UdLl49_PH1Sdw-I_J4bV6fwHrcDqNhE-uhCKXN9BNBjtjTPGaiO2pAuy9XPSFM9eOG2xOScP_35X67-zJP7aj_bvoTscj8XgD_D20E5r76NakOyl_gH4dlYfl-LjEr49Kn3Jdmxk-bJsZWZXLMzxuVvMuCRamFq-PyzcfcNRsaMEwMBBZbDEnFnqeL-0sybpit1hHVQUMu5tvwTyCx12i-wK-pus_8CY9pFtByfysz06P8OPTq1gehuO_voTieYNnG81r3JdqPUTT_fL7lwPS3dBAnBR0RahwSnjnBfeygFhaBam1Z8zlIZfUs2LkJBAoK0LuLK1VBRahLMx6qEaO-4o_QrtN24THCBfS8rqoaW5ZFDED5ueprHJe6cApPMvQ2x4ac74R4jApgNHKbIA0AKRJQJrLDH2O6G17RhHt9KBdzkznk0Y6CG6D1aEQDl4rt1FrXnjOam1rQV2GXkXsTTQ-QNrZrmIBXjiKZplxHmuc8kLLDO0NegIGbtjcW4_pLdwwrQpg61rzDL3YNseRMe2tCe069smBwUOEqjKkB1Y3-GXDlmZ-mmTCaZTqAXb95P-HPkW3WXKPgjC9h3ZXy3V4BiRsVT1PnvUb4vE0TQ priority: 102 providerName: Scholars Portal |
Title | RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice |
URI | https://www.proquest.com/docview/2869800883 https://search.proquest.com/docview/2870992596 https://pubmed.ncbi.nlm.nih.gov/PMC10537226 https://doaj.org/article/5c409ea8e94c46a7a93554d32f8af41c |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVtB2MvY5_MXRc0GGxjqIktWZb35haXEppSkhXyJmRJTgOJHdKEsv-1H7gr2S7z9raHOMaSQfbR1T3XvvcYoU8pNSLUcUGigkGAoiJBFNByAtQhtSNa6pF29c6Ta355y8bzeH6AeFcL45P2dbE8rVbr02p553MrN2s97PLEhjeT89CJkABvGB6iQ_C_XYzerL_gYSnrymMEH97DKu3fVcIv4YyTh54L8kr9_67Hf-dI_uF0Ll6g5y1bxFkzqpfowFav0NNJ-z78Nfo1za_ybJbjL9Pc-IzWaoGv6mpBdvl2jbNqt2xTXeEG4v0s__odO2WGGuDHQFexwpQo6LnZqoUXb8V6tXfaCRh8mKlhEliD23T2Fez6j3zgJgmkXSfJct3loDuQ8d1PVwSG3bNdEuJlhReNsjXuCrLeoNuL_Mf5JWm_w0B0zMIdCZnmzGjDqIlTiJi5jYUwUaQTm8ShidKRjoEmKWYTrcKSF4A7V3DXbTHS1BT0LTqq6sq-QziNFS3TMkxU5KTKgN-ZMC4SWghLQzgWoG8dNHLTyG1IH6YILhsgJQApPZDyIUBnDr3Hnk4q2x-otwvZThgZawhhrRI2ZRqGlSinKM8MjUqhShbqAH122Etn0IC0Vm1dAgzYSWPJLHGVTEkq4gCd9HoCBrrf3M0e2S4E9zISPAVOLgQN0MfHZnemS26rbL13fRLg6RCH8gCJ3qzrXVm_BWzDi4F3tnD8_6e-R88ibx4picQJOtpt9_YDUK1dMQD7micD9CTLxrMx_J_l1zfTgX9wAdsJEwNve78Bv4QyiQ |
link.rule.ids | 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793,73745,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFLWgk4CXiU8RNsBISICQtSaxHYcX1KFMBdoKdZu0N8uxna7SlpR-aOJ_8QO5dp1CQOKhUhW7apJzfX2ufe8xQq_z1IhYs5IkJYUARSWCKKDlBKhDbvtppfva1TuPJ3x4Tr9csIuw4LYKaZWtT_SO2jTarZEfJYLnQG6ESD8uvhN3apTbXQ1HaNxGe045nfXQ3nEx-Tbd7SNkgtO2VEbwoxV4bL9vCZ-MU05uOtORV-3_1zf_nS_5xwR0ch_tB-aIB1uoH6Bbtn6I7ozD3vgj9HNajIrBaYHfTgvjs1vrGR419Yysi-U1HtTreUh7hZeJN6fFuw_YqTQ0YAoYqCtWOCUKei6WauaFXLG-2jgdBQzzmWnAIKzBIbX9Cr76Az_wNiEk-Ewyv27z0R3g-PKHKwjDbp2XxHhe49lW5Rq3xVmP0flJcfZpSMKZDEQzGq9JTDWnRhuaGpZD9MwtE8Ikic5sxmKT5H3NgDIpajOt4oqXYANcwVu3ZV-npkyfoF7d1PYpwjlTaZVXcaYSJ1sGXM_ErMzSUtg0hmsRet9CIxdb6Q3pQxbB5RZICUBKD6S8idCxQ2_X08lm-wvNcibDKJRMQzhrlbA51XBbmXLq8tSkSSVURWMdoTcOe-kGNyCtVahRgBt2MllykLmqpiwXLEKHnZ6Age42t9Yjg1NYyd8mHKFXu2b3S5foVttm4_pkwNkhJuUREh2r6zxZt6WeX3ph8NiJ8wCffvb_f3-J7g7PxiM5-jz5eoDuJX445CQRh6i3Xm7sc6BZ6_JFGEu_AMPiKXg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwGLWgkyZeEFeRMcBISICQ1Sa-xOEFdZBqQFdNHZP2Zjm201XaktKLJv4XP5DPqVMISDxUimJHTfJdfByf7xihVxm1Mja8IEnBYIKiE0k0wHIC0CFzA1qagfH1zicTcXzOvlzwi8B_WgVaZZsTm0Rta-O_kfcTKTIAN1LSfhloEaefRh8W34nfQcqvtIbtNG6jPRgVB0kP7R3lk9Ppbk0hlYK1ZTNS9FeQvZs1TPilggly0xmaGgX_f_P039zJPwaj0T10N6BIPNya_T665aoHaP8krJM_RD-n-TgfnuX4zTS3DdO1muFxXc3IOl9e42G1ngcKLLxYvDnL377HXrGhBrfAAGOxxpRo6LlY6lkj6orN1cZrKmAY22wNzuEsDjT3KzhsNv_AW3JIyJ9kft1y073x8eUPXxyG_TdfEuN5hWdbxWvcFmo9Quej_NvHYxL2ZyCGs3hNYmYEs8YyankGM2nhuJQ2SUzqUh7bJBsYDvBJM5caHZeiAH8QGt66KwaG2oI-Rr2qrtwThDOuaZmVcaoTL2EGuM_GvEhpIR2N4VyE3rWmUYutDIdqpi9SqK0hFRhSNYZUNxE68tbb9fQS2s2JejlTISIVNzC1dVq6jBm4rVR7pXlmaVJKXbLYROi1t73ygQ6WNjrUK8ANe8ksNUx9hVOaSR6hw05PsIHpNrfeo0KCWKnf7hyhl7tmf6UnvVWu3vg-KeB3mJ-KCMmO13WerNtSzS8bkfDYC_UAtj74_7-_QPsQRmr8efL1KbqTNNGQkUQeot56uXHPAHGti-chlH4BiuQtpQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RELEASE+%28REdressing+Long-tErm+Antidepressant+uSE%29%3A+protocol+for+a+3-arm+pragmatic+cluster+randomised+controlled+trial+effectiveness-implementation+hybrid+type-1+in+general+practice&rft.jtitle=Trials&rft.au=Wallis%2C+Katharine+A.&rft.au=Donald%2C+Maria&rft.au=Horowitz%2C+Mark&rft.au=Moncrieff%2C+Joanna&rft.date=2023-09-28&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=24&rft_id=info:doi/10.1186%2Fs13063-023-07646-w&rft.externalDBID=PMC10537226 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |